Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors


Title

Colorectal Cancer - Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors

Therapeutic Area Colorectal Cancer
Principal Investigator Wasif Saif, MD
Min Age 18 Years
Gender Both
Contact Jennifer Caplain, RN
617-636-9161
More Information http://clinicaltrials.gov/ct2/show/NCT01288989

Overview

The purpose of this study is see how safe IM-3C5 is when given to subjects and to determine the best administering dose. We want to see what effects, good and/or bad, the study drug has on you and your tumor.

Study Details

Inclusion Criteria

  • Subject has a histologic or cytologic confirmation of cancer
  • Subjects with advanced/metastatic colorectal cancer that is refractory to standard therapy

Exclusion Criteria

  • Subject has lymphoma or leukemia
  • Subject has undergone a major surgical procedure, radiation therapy, open biopsy, radiofrequency ablation, or has experienced a significant traumatic injury within 28 days prior to enrollment
  • Subject has known or suspected brain or leptomeningeal metastases

Study Requirements

All subjects in the study will receive IMC-3C5 through a needle in their vein over 90 minutes. Subjects will be dosed every week. Subjects with colorectal cancer, will receive 30 mg/kg once weekly. All cycles will consist of 4 weekly doses of the study drug and will last 4 weeks. The study requires physical exams, blood work, ECG, and other exams as needed.